Status:
COMPLETED
Integrated Biomarker And Imaging Study - 2
Lead Sponsor:
GlaxoSmithKline
Conditions:
Atherosclerosis
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
IBIS-2 is a study using SB-480848 versus placebo in subjects with angiographically documented coronary heart disease. Endpoints include coronary imaging, endothelial function, biomarkers, safety and t...
Detailed Description
Integrated Biomarker and Imaging Study -2 (IBIS-2): An International, Multicenter, Randomized, Placebo-controlled, Parallel-group, 1 Year Treatment, Integrated Biomarkers and Imaging Study in Subjects...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Successful PCI (Percutaneous Coronary Intervention) or uncomplicated diagnostic catheterization
- Suitable non-intervened coronary artery with IVUS
- Antiplatelet therapy
- Exclusion criteria:
- Clinical instability
- Previous CABG (Coronary Artery By-pass Graft) surgery
- Planned major surgery
- Recent stroke
- Abnormal QTc
- Renal or hepatic impairment
- Uncontrolled hypertension
- Use of corticosteroids
- Class III or IV heart failure
- Asthma
Exclusion
Key Trial Info
Start Date :
November 10 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 28 2007
Estimated Enrollment :
336 Patients enrolled
Trial Details
Trial ID
NCT00268996
Start Date
November 10 2005
End Date
August 28 2007
Last Update
March 20 2018
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Vienna, Austria, A-1140
2
GSK Investigational Site
Aalst, Belgium, 9300
3
GSK Investigational Site
Antwerp, Belgium, 2020
4
GSK Investigational Site
Liège, Belgium, 4000